LPCNLipocineLPCN info
$4.87info4.06%24h
Global rank27090
Market cap$25.89M
Change 7d-1.62%
YTD Performance76.45%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Lipocine (LPCN) Stock Overview

    Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

    LPCN Stock Information

    Symbol
    LPCN
    Address
    675 Arapeen DriveSalt Lake City, UT 84108United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.lipocine.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    801 994 7383

    Lipocine (LPCN) Price Chart

    -
    Value:-

    Lipocine Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $4.87
    N/A
    Market Cap
    $25.89M
    N/A
    Shares Outstanding
    5.32M
    N/A
    Employees
    17.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org